A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease
Descripción del Articulo
First, we would like to acknowledge and thank all the patients for willingly participating in medical research and making advancement in the care of patients with sickle cell disease possible. VAS is supported by an American Society of Hematology Scholar Award, and National Heart, Lung and Blood Ins...
| Autores: | , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2018 |
| Institución: | Consejo Nacional de Ciencia Tecnología e Innovación |
| Repositorio: | CONCYTEC-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.concytec.gob.pe:20.500.12390/502 |
| Enlace del recurso: | https://hdl.handle.net/20.500.12390/502 https://doi.org/10.1097/MPH.0000000000001177 |
| Nivel de acceso: | acceso abierto |
| Materia: | hydroxyurea hemoglobin absolute neutrophil count absolute reticulocyte count age https://purl.org/pe-repo/ocde/ford#3.02.00 |
| id |
CONC_cc88b5c668767bfd5e6ff73594901b9d |
|---|---|
| oai_identifier_str |
oai:repositorio.concytec.gob.pe:20.500.12390/502 |
| network_acronym_str |
CONC |
| network_name_str |
CONCYTEC-Institucional |
| repository_id_str |
4689 |
| dc.title.none.fl_str_mv |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| title |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| spellingShingle |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease George P.E. hydroxyurea hemoglobin absolute neutrophil count absolute reticulocyte count age https://purl.org/pe-repo/ocde/ford#3.02.00 |
| title_short |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| title_full |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| title_fullStr |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| title_full_unstemmed |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| title_sort |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease |
| author |
George P.E. |
| author_facet |
George P.E. Bazo-Alvarez J.C. Sheehan V.A. |
| author_role |
author |
| author2 |
Bazo-Alvarez J.C. Sheehan V.A. |
| author2_role |
author author |
| dc.contributor.author.fl_str_mv |
George P.E. Bazo-Alvarez J.C. Sheehan V.A. |
| dc.subject.none.fl_str_mv |
hydroxyurea |
| topic |
hydroxyurea hemoglobin absolute neutrophil count absolute reticulocyte count age https://purl.org/pe-repo/ocde/ford#3.02.00 |
| dc.subject.es_PE.fl_str_mv |
hemoglobin absolute neutrophil count absolute reticulocyte count age |
| dc.subject.ocde.none.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.02.00 |
| description |
First, we would like to acknowledge and thank all the patients for willingly participating in medical research and making advancement in the care of patients with sickle cell disease possible. VAS is supported by an American Society of Hematology Scholar Award, and National Heart, Lung and Blood Institute, 1K08DK110448-01. JCBA has been sponsored by Cienciactiva, an initiative of the Peruvian National Council of Science, Technology and Technological Innovation (CONCYTEC); grant contract number 231-2015-FONDECYT. PEG would also like to thank Dr. Alex George for access to clinical data and help with the study preparation and conceptualization. |
| publishDate |
2018 |
| dc.date.accessioned.none.fl_str_mv |
2024-05-30T23:13:38Z |
| dc.date.available.none.fl_str_mv |
2024-05-30T23:13:38Z |
| dc.date.issued.fl_str_mv |
2018 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12390/502 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1097/MPH.0000000000001177 |
| dc.identifier.scopus.none.fl_str_mv |
2-s2.0-85049264120 |
| url |
https://hdl.handle.net/20.500.12390/502 https://doi.org/10.1097/MPH.0000000000001177 |
| identifier_str_mv |
2-s2.0-85049264120 |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.none.fl_str_mv |
Journal of Pediatric Hematology/Oncology |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Lippincott Williams and Wilkins |
| publisher.none.fl_str_mv |
Lippincott Williams and Wilkins |
| dc.source.none.fl_str_mv |
reponame:CONCYTEC-Institucional instname:Consejo Nacional de Ciencia Tecnología e Innovación instacron:CONCYTEC |
| instname_str |
Consejo Nacional de Ciencia Tecnología e Innovación |
| instacron_str |
CONCYTEC |
| institution |
CONCYTEC |
| reponame_str |
CONCYTEC-Institucional |
| collection |
CONCYTEC-Institucional |
| repository.name.fl_str_mv |
Repositorio Institucional CONCYTEC |
| repository.mail.fl_str_mv |
repositorio@concytec.gob.pe |
| _version_ |
1844883037419995136 |
| spelling |
Publicationrp00646600rp00647600rp00648600George P.E.Bazo-Alvarez J.C.Sheehan V.A.2024-05-30T23:13:38Z2024-05-30T23:13:38Z2018https://hdl.handle.net/20.500.12390/502https://doi.org/10.1097/MPH.00000000000011772-s2.0-85049264120First, we would like to acknowledge and thank all the patients for willingly participating in medical research and making advancement in the care of patients with sickle cell disease possible. VAS is supported by an American Society of Hematology Scholar Award, and National Heart, Lung and Blood Institute, 1K08DK110448-01. JCBA has been sponsored by Cienciactiva, an initiative of the Peruvian National Council of Science, Technology and Technological Innovation (CONCYTEC); grant contract number 231-2015-FONDECYT. PEG would also like to thank Dr. Alex George for access to clinical data and help with the study preparation and conceptualization.Hydroxyurea (HU) has proven hematologic and clinical benefits, especially when escalated to the maximum tolerated dose (MTD). We reviewed clinical data from patients with sickle cell disease (January 2011 to 2016) to determine baseline sociodemographic and laboratory parameters associated with reaching HU MTD without significant delays. In total, 210 patients (mean HU start age, 6.6 y) were included. Initial Kaplan-Meier event analysis showed 1 year to be an inflection point for reaching MTD. In total, 116 patients (55%) reached MTD in <1 year, with 56 (27%) taking >1 year to reach MTD and 38 (18%) patients not successfully reaching MTD during follow-up. In both crude and adjusted analyses, age at HU start was found to be significantly and inversely associated with reaching MTD within 1 year. The data presented, specifically the inflection point of reaching MTD at 1 year and the association of young HU start age with reaching MTD within a year, suggest that successful achievement of MTD may be facilitated by starting patients on HU at a young age and that older patients should receive additional intervention to attain MTD within 1 year. Patients who do not achieve MTD within a year may need the most extensive intervention.Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica - ConcytecengLippincott Williams and WilkinsJournal of Pediatric Hematology/Oncologyinfo:eu-repo/semantics/openAccesshydroxyureahemoglobin-1absolute neutrophil count-1absolute reticulocyte count-1age-1https://purl.org/pe-repo/ocde/ford#3.02.00-1A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Diseaseinfo:eu-repo/semantics/articlereponame:CONCYTEC-Institucionalinstname:Consejo Nacional de Ciencia Tecnología e Innovacióninstacron:CONCYTEC#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#20.500.12390/502oai:repositorio.concytec.gob.pe:20.500.12390/5022024-05-30 15:22:00.283http://purl.org/coar/access_right/c_14cbinfo:eu-repo/semantics/closedAccessmetadata only accesshttps://repositorio.concytec.gob.peRepositorio Institucional CONCYTECrepositorio@concytec.gob.pe#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="dabf6e36-0fe2-4d42-9598-643e8db57733"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated with Achieving Optimal Hydroxyurea Therapy in Children with Sickle Cell Disease</Title> <PublishedIn> <Publication> <Title>Journal of Pediatric Hematology/Oncology</Title> </Publication> </PublishedIn> <PublicationDate>2018</PublicationDate> <DOI>https://doi.org/10.1097/MPH.0000000000001177</DOI> <SCP-Number>2-s2.0-85049264120</SCP-Number> <Authors> <Author> <DisplayName>George P.E.</DisplayName> <Person id="rp00646" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Bazo-Alvarez J.C.</DisplayName> <Person id="rp00647" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Sheehan V.A.</DisplayName> <Person id="rp00648" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Lippincott Williams and Wilkins</DisplayName> <OrgUnit /> </Publisher> </Publishers> <Keyword>hydroxyurea</Keyword> <Keyword>hemoglobin</Keyword> <Keyword>absolute neutrophil count</Keyword> <Keyword>absolute reticulocyte count</Keyword> <Keyword>age</Keyword> <Abstract>Hydroxyurea (HU) has proven hematologic and clinical benefits, especially when escalated to the maximum tolerated dose (MTD). We reviewed clinical data from patients with sickle cell disease (January 2011 to 2016) to determine baseline sociodemographic and laboratory parameters associated with reaching HU MTD without significant delays. In total, 210 patients (mean HU start age, 6.6 y) were included. Initial Kaplan-Meier event analysis showed 1 year to be an inflection point for reaching MTD. In total, 116 patients (55%) reached MTD in <1 year, with 56 (27%) taking >1 year to reach MTD and 38 (18%) patients not successfully reaching MTD during follow-up. In both crude and adjusted analyses, age at HU start was found to be significantly and inversely associated with reaching MTD within 1 year. The data presented, specifically the inflection point of reaching MTD at 1 year and the association of young HU start age with reaching MTD within a year, suggest that successful achievement of MTD may be facilitated by starting patients on HU at a young age and that older patients should receive additional intervention to attain MTD within 1 year. Patients who do not achieve MTD within a year may need the most extensive intervention.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication> -1 |
| score |
13.394457 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
